SAN DIEGO--(BUSINESS WIRE)--Mar. 6, 2018--
Heron Therapeutics, Inc. (NASDAQ: HRTX), a commercial-stage
biotechnology company focused on improving the lives of patients by
developing best-in-class treatments to address some of the most
important unmet patient needs, announced that Barry D. Quart, Pharm.D.,
Chief Executive Officer of Heron Therapeutics, will present at the 38th
Annual Cowen Healthcare Conference on Monday, March 12, 2018, at 3:30
p.m. EST at the Boston Marriott Copley Place.
A live webcast of this presentation will be available on the Company’s
website at www.herontx.com in
the Investor Resources section. A replay of the presentation will be
archived on the site for 60 days.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company
focused on improving the lives of patients by developing best-in-class
treatments that address some of the most important unmet patient needs.
Heron is developing novel, patient-focused solutions that apply its
innovative science and technologies to already-approved pharmacological
agents for patients suffering from cancer or pain. For more information,
This news release contains "forward-looking statements" as defined by
the Private Securities Litigation Reform Act of 1995. Heron cautions
readers that forward-looking statements are based on management’s
expectations and assumptions as of the date of this news release and are
subject to certain risks and uncertainties that could cause actual
results to differ materially. These risks and uncertainties include, but
are not limited to, risks and uncertainties identified in the Company's
filings with the Securities and Exchange Commission. Forward-looking
statements reflect our analysis only on their stated date, and Heron
takes no obligation to update or revise these statements except as may
be required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180306006294/en/
Source: Heron Therapeutics, Inc.
Senior VP, General Counsel, Business Development and
Heron Therapeutics, Inc.